Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABIG vs BOLD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BOLD Wins Head-to-Head Institutional Verdict (2–1 across 6 Pillars · 6–2 Matrix Metrics)

BOLD Overall Winner 6-Pillar Tally: ABIG 1 – 2 BOLD (3 Tie) Matrix Metrics: ABIG 2 – 6 BOLD

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) is the stronger overall head-to-head candidate over Argent Large Cap ETF (ABIG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). ABIG carries a Unified Composite Score of 46.8/100 (HOLD) at $31.73 (N/M Forward P/E, N/A operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While ABIG currently prints a higher short-term Unified Composite Score (46.8/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: ABIG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABIG vs BOLD
ABIG NASDAQ
Argent Large Cap ETF
Institutional Equity
$31.73
-3.67% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.02β · 22% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 36.0 Fund 48.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.1%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $34.23 · SMA50: $34.95
BOLD NASDAQ Head-to-Head Winner
Boundless Bio, Inc. Common Stock
Pharmaceutical Preparations
$2.32
-2.52% 1D
Market Cap $56.2M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -0.08β · 28% Vol
Unified Composite Score
36.8 / 100 SELL
Tech 25.0 Fund 50.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.6%), weak momentum, RSI 35
RSI-14: 35.0 · SMA20: $2.43 · SMA50: $2.52

6-Pillar Scorecard Institutional Category Breakdown (ABIG 1 – 2 BOLD)

Columns: Metric · ABIG · BOLD
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale BOLD
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A N/A
Market Cap N/A $56.2M
3. Profitability & Quality BOLD
Gross Margin N/A N/A
Operating Margin N/A 0.0%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -64.6%
4. Balance Sheet & Cash Flow ABIG
Cash Generation (TTM) N/A -$48M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $31M Net Debt (0.56x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABIG (2) vs BOLD (6)
Institutional Metric ABIG BOLD Criterion Row Edge
Market Capitalization
Scale
N/A $56.2M Larger Scale BOLD
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth BOLD
Operating Margin (TTM)
Profitability
N/A 0.0% Higher Margin BOLD
Net Profit Margin
Profitability
N/A 0.0% Higher Margin BOLD
Return on Equity (ROE)
Capital Efficiency
N/A -64.6% Higher ROE BOLD
52-Week Range Position
Momentum
41% ($28–$36) 62% ($1–$3) Stronger Trend BOLD
Beta / 30D Volatility
Risk Regime
1.02β · 22% Vol -0.08β · 28% Vol Lower Realized Risk ABIG
Unified Institutional Score
Composite Signal
46.8 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite ABIG
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$48M ($31M Net Debt (0.56x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon BOLD +4.73 pp
ABIG: -9.65% · BOLD: -4.92%
3M Horizon ABIG +11.89 pp
ABIG: -9.73% · BOLD: -21.62%
6M Horizon BOLD +66.72 pp
ABIG: -5.61% · BOLD: +61.11%
1Y Horizon BOLD +100.15 pp
ABIG: +1.59% · BOLD: +101.74%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABIG vs BOLD. Trailing 12-month operating profitability (ABIG N/A vs BOLD 0.0%) and valuation multiples (ABIG N/M vs BOLD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABIG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
BOLD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.6% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABIG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABIG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
BOLD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact BOLD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABIG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
BOLD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $56.2M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABIG vs BOLD Key Questions & Quantitative Answers

As of Nov 20, 2026, Boundless Bio, Inc. (BOLD) is the stronger overall head-to-head candidate over Argent Large Cap ETF (ABIG) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 2–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). ABIG carries a Unified Composite Score of 46.8/100 (HOLD) at $31.73 (N/M Forward P/E, N/A operating margin), whereas BOLD carries 36.8/100 (SELL) at $2.32 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While ABIG currently prints a higher short-term Unified Composite Score (46.8/100 HOLD vs. BOLD 36.8/100 SELL), BOLD captures the overall institutional head-to-head verdict (6–2 matrix metrics and 2–1 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: ABIG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile BOLD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 35.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

BOLD leads the Growth & Scale pillar: ABIG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with BOLD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, ABIG generates N/A in USD-normalized revenue versus N/A for BOLD. In operating R&D and SG&A reinvestment, ABIG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BOLD.

ABIG and BOLD trade at balanced relative valuation multiples. ABIG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas BOLD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABIG (N/A ROE) versus BOLD (-64.6% ROE) capital efficiency.

In options market volatility and institutional positioning, ABIG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.02β · 22% Vol realized risk). By comparison, BOLD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.08β · 28% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.